Gene knockdown studies revealed CCDC50 as a candidate gene in mantle cell lymphoma and chronic lymphocytic leukemia

[1]  Paul D. P. Pharoah,et al.  p53 polymorphisms: cancer implications , 2009, Nature Reviews Cancer.

[2]  S. Hatakeyama,et al.  Inhibition of NF-kappaB signaling via tyrosine phosphorylation of Ymer. , 2009, Biochemical and biophysical research communications.

[3]  H. Döhner,et al.  Treatment resistance in chronic lymphocytic leukemia–the role of the p53 pathway , 2009, Leukemia & lymphoma.

[4]  E. Campo,et al.  Integrated genomic and expression profiling in mantle cell lymphoma: identification of gene‐dosage regulated candidate genes , 2008, British journal of haematology.

[5]  E. Campo,et al.  Advances in the understanding of mantle cell lymphoma , 2008, British journal of haematology.

[6]  P. Lichter,et al.  Off-target effects of siRNA specific for GFP , 2008, BMC Molecular Biology.

[7]  Michael Hallek,et al.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.

[8]  H. Müller-Hermelink,et al.  Genomic aberrations in mantle cell lymphoma detected by interphase fluorescence in situ hybridization. Incidence and clinicopathological correlations , 2008, Haematologica.

[9]  S. Hatakeyama,et al.  Involvement of Ymer in suppression of NF-kappaB activation by regulated interaction with lysine-63-linked polyubiquitin chain. , 2008, Biochimica et biophysica acta.

[10]  J. Phang,et al.  The metabolism of proline, a stress substrate, modulates carcinogenic pathways , 2008, Amino Acids.

[11]  Hartmut Döhner,et al.  Molecular diagnostics in chronic lymphocytic leukemia – Pathogenetic and clinical implications , 2008, Leukemia & lymphoma.

[12]  O. Clausen,et al.  Apoptosis, cell cycle progression and gene expression in TP53-depleted HCT116 colon cancer cells in response to short-term 5-fluorouracil treatment. , 2007, International journal of oncology.

[13]  L. Staudt,et al.  Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Hiromi Nabeshi,et al.  Suppression of the Ligand-mediated Down-regulation of Epidermal Growth Factor Receptor by Ymer, a Novel Tyrosine-phosphorylated and Ubiquitinated Protein* , 2006, Journal of Biological Chemistry.

[15]  H. Döhner,et al.  Antagonizing inactivated tumor suppressor genes and activated oncogenes by a versatile transgenesis system: application in mantle cell lymphoma , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  F. Cavalli,et al.  Update on the molecular biology of mantle cell lymphoma , 2006, Hematological oncology.

[17]  L. Staudt,et al.  Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[18]  M. Spinella,et al.  A p53-dominant transcriptional response to cisplatin in testicular germ cell tumor-derived human embyronal carcinoma , 2005, Oncogene.

[19]  G. Gahrton,et al.  Identification of progression markers in B-CLL by gene expression profiling. , 2005, Experimental hematology.

[20]  M. Zago,et al.  Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K‐AKT, WNT and TGFβ signalling pathways , 2005, British journal of haematology.

[21]  D. Pinkel,et al.  Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. , 2005, Blood.

[22]  Marc K Hellerstein,et al.  In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. , 2005, The Journal of clinical investigation.

[23]  H. Tagawa,et al.  Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM , 2005, Oncogene.

[24]  Rolph Pfundt,et al.  Novel chromosomal imbalances in mantle cell lymphoma detected by genome-wide array-based comparative genomic hybridization. , 2005, Blood.

[25]  Ola Snøve,et al.  Designing effective siRNAs with off-target control. , 2004, Biochemical and biophysical research communications.

[26]  R. Abseher,et al.  Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Randy D Gascoyne,et al.  Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes. , 2004, Human molecular genetics.

[28]  G. Ott,et al.  Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions. , 2004, Blood.

[29]  S. Schmechel,et al.  Identification of genes whose expression patterns differ in benign lymphoid tissue and follicular, mantle cell, and small lymphocytic lymphoma , 2004, Leukemia.

[30]  Martin Schuler,et al.  Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis , 2004, Science.

[31]  Nerea Martínez,et al.  The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. , 2003, Cancer research.

[32]  L. Pham,et al.  Inhibition of Constitutive NF-κB Activation in Mantle Cell Lymphoma B Cells Leads to Induction of Cell Cycle Arrest and Apoptosis1 , 2003, The Journal of Immunology.

[33]  B. Li,et al.  Expression profiling reveals off-target gene regulation by RNAi , 2003, Nature Biotechnology.

[34]  F. Holstege,et al.  Specific inhibition of gene expression using a stably integrated, inducible small‐interfering‐RNA vector , 2003, EMBO reports.

[35]  S. de Vos,et al.  Cell Cycle Alterations in the Blastoid Variant of Mantle Cell Lymphoma (MCL-BV) as Detected by Gene Expression Profiling of Mantle Cell Lymphoma (MCL) and MCL-BV , 2003, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[36]  L. Staudt,et al.  The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. , 2003, Cancer cell.

[37]  J. Kere,et al.  Investigatory and analytical approaches to differential gene expression profiling in mantle cell lymphoma , 2002, British journal of haematology.

[38]  H. Döhner,et al.  Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes. , 2002, Blood.

[39]  Judith Roth,et al.  A polymorphic microsatellite that mediates induction of PIG3 by p53 , 2002, Nature Genetics.

[40]  S. de Vos,et al.  Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. , 2001, Blood.

[41]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[42]  R. Beyaert,et al.  A20 and A20-binding proteins as cellular inhibitors of nuclear factor-kappa B-dependent gene expression and apoptosis. , 2000, Biochemical pharmacology.

[43]  R. Eisenman,et al.  Analysis of Myc/Max/Mad network members in adipogenesis: Inhibition of the proliferative burst and differentiation by ectopically expressed Mad1 , 2000, Journal of cellular physiology.

[44]  H. Döhner,et al.  Mantle cell lymphoma is characterized by inactivation of the ATM gene. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Michael Baudis,et al.  t(11;14)‐positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B‐cell chronic lymphocytic leukemia , 2000, Genes, chromosomes & cancer.

[46]  A. López-Guillermo,et al.  Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. , 1999, Blood.

[47]  K. Franssila,et al.  Gain of 3q and deletion of 11q22 are frequent aberrations in mantle cell lymphoma , 1998, Genes, chromosomes & cancer.

[48]  P. Lichter,et al.  Specific chromosomal imbalances in human papillomavirus-transfected cells during progression toward immortality. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[49]  C. Ferran,et al.  A20 Blocks Endothelial Cell Activation through a NF-κB-dependent Mechanism* , 1996, The Journal of Biological Chemistry.

[50]  G. Cooper,et al.  Activation of the CPP32 Apoptotic Protease by Distinct Signaling Pathways with Differential Sensitivity to Bcl-xL* , 1996, The Journal of Biological Chemistry.

[51]  P. O'Connor,et al.  Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. , 1994, Science.

[52]  S. Chevret,et al.  B-cell chronic lymphocytic leukemia: present status and future directions. French Cooperative Group on CLL. , 1991, Blood.

[53]  P. Nowell,et al.  Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. , 1984, Science.

[54]  P. Nowell,et al.  The chromosome 14 breakpoint in neoplastic B cells with the t(11;14) translocation involves the immunoglobulin heavy chain locus. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[55]  H. Döhner,et al.  Efficient nucleofection of primary human B cells and B-CLL cells induces apoptosis, which depends on the microenvironment and on the structure of transfected nucleic acids , 2007, Leukemia.

[56]  Juan F. García,et al.  Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. , 2007, Blood.